{"nctId":"NCT00289874","briefTitle":"Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)","startDateStruct":{"date":"2006-03"},"conditions":["Asthma"],"count":421,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: montelukast sodium"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"montelukast sodium","otherNames":["MK0476"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients, ages 6 to 14 years, with persistent asthma that is also active during allergy season\n* Patients must demonstrate positive skin prick tests to seasonally relevant geographic aeroallergens\n\nExclusion Criteria:\n\n* Patient cannot have any other acute or chronic pulmonary disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"14 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3","description":"Percent change from baseline in FEV1, a measure of airway function, at Week 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.53","spread":null},{"groupId":"OG001","value":"9.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Daily \"as Needed\" β-agonist Use Over the 3-week Treatment Period","description":"Percent change from baseline in average daily β-agonist use over the 3-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.88","spread":"84.75"},{"groupId":"OG001","value":"-12.40","spread":"53.88"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":203},"commonTop":[]}}}